Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
487.32
+22.61 (4.87%)
NASDAQ · Last Trade: Feb 17th, 4:27 PM EST
Detailed Quote
Previous Close
464.71
Open
462.37
Bid
487.31
Ask
487.59
Day's Range
462.04 - 495.00
52 Week Range
265.00 - 615.00
Volume
403,047
Market Cap
8.33B
PE Ratio (TTM)
-37.81
EPS (TTM)
-12.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
326,128
Chart
About Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for liver and metabolic diseases, with an emphasis on addressing non-alcoholic steatohepatitis (NASH) and related conditions. The company’s research and development efforts center around its proprietary drug candidates that target and modulate key metabolic pathways, aiming to improve patient outcomes and provide effective treatment options. By leveraging cutting-edge science and clinical expertise, Madrigal is dedicated to advancing its pipeline of transformative therapies to meet the growing needs of patients suffering from complex liver diseases. Read More
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake.
